Medicinal coating layer supporting frame for preventing/treating renarrowing after inbellow arteria coronaria shaping operation

A coronary artery and drug-coated technology, which is applied in the fields of medical equipment, surgery, and medical science, can solve the problems of stents affecting the efficacy of PTCA, improve survival rate and quality of life, reduce tissue rejection, and reduce surgical complications disease effect

Inactive Publication Date: 2004-10-06
SHANGHAI MICROPORT MEDICAL (GROUP) CO LTD
View PDF1 Cites 18 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, in-stent restenosis has become the main problem and fatal weakness affecting the efficacy of PTCA.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Add 0.20g polybutylmethacrylate and 0.20g ethylene-vinyl acetate copolymer into 10ml trichloroethane, mix and disperse evenly, then add 0.10g Simvastatin (simvastatin), disperse evenly at room temperature, and then spray on bracket surface. Cured in air for 30min. Repeat the above operation until the drug load reaches the requirement (about 50-300 μg / cm 2 ). The stent was then dried in a vacuum oven for 0.5 hours.

Embodiment 2

[0027] Add 0.20g of polybutylmethacrylate and 0.20g of ethylene-vinyl acetate copolymer into 10ml of trichloroethane, mix and disperse evenly, then add 0.10g of Zinostatin, disperse evenly at room temperature, and then spray on the surface of the stent. Cured in air for 30min. Repeat the above operation until the drug load reaches the requirement (about 50-300 μg / cm 2 ). The scaffolds were then dried in a vacuum oven for 10 hours.

Embodiment 3

[0029] Add 0.20g polybutylmethacrylate and 0.20g ethylene-vinyl acetate copolymer to 10ml trichloroethane, mix and disperse evenly, then add 0.075g Cilostazol and 0.10g Simvastatin, disperse evenly at room temperature, and then spray on the surface of the stent . Cured in air for 30min. Repeat the above operations until the weight of the drug-loaded layer reaches the requirement (about 150-200 μg / cm 2 ). Then the stent was placed in a vacuum oven at 30° C. and vacuumed for 24 hours. In order to prevent the adhesion between the drug coating and the balloon, a layer of Parylene or its derivatives can be coated on the surface of the stent by vapor deposition, and its thickness is controlled between 0.01-10 microns.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

A medicine coated scaffold for preventing and treating the renarrowing of arteria coronaria after plastic operation features that the tatin kind of medicines which can suppress the growth of new tunia intime and the reproduction of smooth muscle cells is contained in the coated layer of scaffold and can be slowly released to prevent said renarrowing of arteria coronaria. Its advantages are high effect and low cost.

Description

technical field [0001] The invention relates to a drug stent, in particular to a stent for preventing / treating restenosis after intracavitary coronary angioplasty. Background technique [0002] The stenosis or obstruction of the lumen caused by atherosclerosis is the main cause of ischemic heart disease (coronary heart disease), resulting in 500,000-600,000 deaths per year. Percutaneous transluminal coronary angioplasty (abbreviated as PTCA, the same below) uses balloon filling to dilate occluded or narrowed blood vessels to restore normal blood supply. It has been widely accepted and applied to the treatment of coronary heart disease. Although the clinical effect of PTCA in the treatment of coronary heart disease is satisfactory, its acute vascular occlusion and postoperative vascular restenosis limit the development of PTCA to a certain extent. According to reports, 10% of patients may experience acute or subacute coronary artery obstruction during PTCA; and the probabili...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61L31/16A61M29/00A61M31/00
Inventor 张一罗七一唐智荣张鹰何水英李俊菲
Owner SHANGHAI MICROPORT MEDICAL (GROUP) CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap